Immunocompromisation- is it aHUS?
Immunocompromisation is a hall mark of aHUS. For those who are predisposed to it and for those who have had it…
Global aHUS at the Baltimore Conference
Global Action will be attending the Foundation’s Baltimore aHUS patients conference from the 28th to the 30th April. Here you will…
The ethics of aHUS patient involvement.
Over the past 10 years the movement of involvement of patients in the development of medicines, their regulation and use has…
aHUS Community Advisory Board News
Two updates on the Global aHUS Community Advisory Board. There is some information about the inaugural set of CAB / PHARMA…
aHUS Global Action – Meet Trustee K Grey
As advocates for the rare disease atypical haemolytic uraemic syndrome (atypical HUS), there’s only one group of patients and caregivers whose…
aHUS in New Zealand
We're so pleased to highlight atypical HUS in New Zealand, with this article written by aHUS family caregiver Anna Benson. No…
aHUS Day 2022: Awareness Through Togetherness
The 8th international aHUS Awareness Day will occur on 24 September 2022, with this year’s theme as ‘Awareness through Togetherness’. We’re…
A Community Advisory Board for aHUS
Today it can be announced that a Global aHUS Community Advisory Board (CAB) has been formed. What is a Community Advisory…
Atypical HUS PROs: Patient Reported Outcomes
What are patient reported outcomes (PROS)? The aHUS Alliance Global Action team look at PROs and their importance in the aHUS space.